NUPR1 (Nuclear Protein 1), also known as p8 or Com1. is a stress-inducible transcriptional regulator implicated in cellular responses to stress, including hypoxia, DNA damage, and nutrient deprivation. Initially identified as a gene upregulated during acute pancreatitis, NUPR1 is a small, intrinsically disordered protein that interacts with chromatin-modifying complexes and transcription factors to regulate gene expression. It plays critical roles in cell proliferation, apoptosis, autophagy, and tumor progression, with overexpression observed in various cancers (e.g., pancreatic, liver, and breast cancers), where it promotes metastasis, chemoresistance, and poor prognosis. NUPR1’s involvement in pathways like TGF-β, ERK, and NF-κB underscores its multifaceted role in oncogenesis and stress adaptation.
NUPR1 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies, often developed against specific epitopes (e.g., N-terminal regions), enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validated antibodies help elucidate NUPR1’s dynamic regulation, interactions with binding partners (e.g., MSL1. ATF5), and its role in stress responses or tumor microenvironments. Research using NUPR1 antibodies has advanced understanding of its dual roles as a tumor suppressor or promoter, depending on cellular context, and its potential as a therapeutic target. However, challenges remain in ensuring antibody specificity due to NUPR1’s low molecular weight (~8 kDa) and structural flexibility, necessitating rigorous validation using knockout controls or epitope-tagged proteins.